SG Americas Securities
RAPT

SG Americas Securities’s RAPT Therapeutics RAPT Stock Holding History

SG Americas Securities’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,000
Closed -$32K – 3169
2021
Q1 		$32K Buy
+3,000
New +$495K ﹤0.01% 3191

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SG Americas Securities's RAPT Position: Q1 2025 in Review

SG Americas Securities sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 6,656 shares — an estimated $84K sold.

SG Americas Securities first reported a position in RAPT in Q2 2020 and held it in 9 quarters. The position peaked at $4.98M in Q3 2021. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • SG Americas Securities reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 6,656 RAPT Therapeutics shares in Q1 2025, an estimated $84K.
  • SG Americas Securities first reported a position in RAPT Therapeutics in Q2 2020 and held it in 9 quarters.
  • SG Americas Securities's RAPT Therapeutics position peaked at $4.98M in Q3 2021.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.